Welcome to our dedicated page for Kronos Bio news (Ticker: KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio stock.
Kronos Bio, Inc. (KRON) is a clinical-stage biopharmaceutical company pioneering small molecule therapeutics that target deregulated transcription in cancer and autoimmune disorders. This page provides investors and industry observers with essential updates on the company’s progress, including clinical trial milestones, financial disclosures, and strategic partnerships.
Access real-time announcements about KRON’s innovative pipeline candidates, including CDK9 and p300 KAT inhibitors designed to address high-need oncology indications. Our curated news collection offers insights into the company’s proprietary discovery engine and precision medicine approach while maintaining compliance with financial reporting standards.
Key updates cover earnings reports, research collaborations, regulatory developments, and scientific presentations. Bookmark this page for streamlined access to KRON’s latest advancements in transcription factor therapeutics and biopharmaceutical innovation.
Kronos Bio (NASDAQ: KRON) presented new preclinical data on istisociclib (KB-0742), a CDK9 inhibitor, at the AACR Ovarian Cancer Research Symposium. The data supports the clinical evaluation of istisociclib in advanced ovarian cancer, particularly in platinum and PARP-inhibitor resistant cases.
Key findings include:
- Istisociclib triggered cell death in preclinical ovarian cancer models resistant to platinum and PARP inhibitors
- New PK/PD results show sustained downregulation of CDK9-dependent genes in PBMCs with an 80mg dose on a 4 days on/3 days off schedule
- Preclinical evidence suggests istisociclib induces DNA damage and subsequent cell death
- Istisociclib disrupted homologous recombination DNA damage repair, creating a "BRCAness" phenotype in resistant cells
Kronos Bio is currently evaluating istisociclib in a Phase 1/2 clinical trial expansion cohort for platinum-resistant high-grade serous ovarian cancer (HGSOC).
Kronos Bio (Nasdaq: KRON), a company developing small molecule therapeutics for cancers and diseases driven by deregulated transcription, has announced its participation in three upcoming conferences in September 2024:
1. H.C. Wainwright 26th Annual Global Investment Conference (Sept 9-11, New York): CEO Norbert Bischofberger will present on Sept 9.
2. AACR 15th Biennial Ovarian Cancer Research Symposium (Sept 20-21, Seattle): A poster on KB-0742, an oral CDK9 inhibitor, will be presented.
3. International Myeloma Society 21st Annual Meeting (Sept 25-28, Brazil): A Kronos Bio collaborator will give an oral presentation on p300 catalytic inhibition in multiple myeloma.
Live audio webcast and posters will be available on the Kronos Bio website.
Kronos Bio (KRON) reported Q2 2024 financial results and pipeline updates. Key highlights include:
1. First patient dosed with istisociclib (KB-0742) in platinum-resistant high-grade serous ovarian cancer; data expected in 1H 2025.
2. KB-9558 IND-enabling studies for multiple myeloma on track for Q4 2024 completion.
3. New potential indication for KB-9558 in HPV-driven tumors announced.
4. New p300 program for autoimmune indications in development.
5. $136.6 million cash position expected to fund operations into 2H 2026.
6. Q2 2024 financial results: R&D expenses $13.8M, G&A expenses $6.4M, net loss $16.2M ($0.27 per share).
Kronos Bio (NASDAQ: KRON) has dosed the first patient in an expansion cohort of its KB-0742 clinical trial, focusing on platinum-resistant high-grade serous ovarian cancer (HGSOC). The trial uses an 80mg dose on a four-days-on, three-days-off schedule, which cleared the dose escalation phase. This dosing regimen is expected to provide a 1.8-fold increase in AUC compared to the previous 60mg three-days-on, four-days-off schedule.
KB-0742 has shown a favorable safety profile in over 100 patients, with no grade 3 or 4 neutropenia observed. The company plans to provide an efficacy update on this expansion cohort in the first half of 2025. HGSOC is particularly sensitive to CDK9 inhibition due to MYC amplification or overexpression and homologous recombination deficiencies, affecting a significant portion of ovarian cancer patients.
Kronos Bio announced new data from its Phase 1/2 trial of KB-0742, presented at the 2024 ASCO Annual Meeting. KB-0742 showed a manageable safety profile with no grade 3/4 neutropenia observed. Dose linear pharmacokinetics were consistent up to 80mg, and increased target engagement was noted at higher doses. The 80mg four-days-on, three-days-off cohort is currently enrolling, with an expansion cohort expected in Q3 2024. Data from 103 patients revealed manageable mild to moderate nausea and vomiting, and less than 10% discontinued due to adverse events. Anti-tumor activity was observed in case studies, and pharmacokinetic modeling predicts increased efficacy at the 80mg dose.
Kronos Bio announces its participation in three upcoming healthcare conferences. CEO Norbert Bischofberger will represent Kronos Bio at these events. On May 28, 2024, he will join a virtual fireside chat at TD Cowen's Oncology Innovation Summit. On June 5, 2024, he will present a corporate overview and host investor meetings at the Jefferies Global Healthcare Conference in New York. Lastly, on June 11, 2024, he will participate in a fireside chat and host investor meetings at the Goldman Sachs Global Healthcare Conference in Miami. Live webcasts of these events will be available on Kronos Bio's website.
Kronos Bio is a clinical-stage company focused on developing small molecule therapeutics for cancers driven by deregulated transcription. Its drug candidates include KB-0742, targeting CDK9 for solid tumors, and KB-9558, targeting p300 for multiple myeloma.
Kronos Bio announced the appointment of Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer, effective June 3, 2024.
Dr. Knobelman brings extensive experience from her previous roles at Senti Bio, Jogo Health, Thinklabs, Aktiv Pharma Group, GeneriCo, and Ampio Pharmaceuticals.
She will oversee finance, accounting, business development, investor relations, and corporate strategy at Kronos Bio.
Dr. Knobelman's addition aims to strengthen the company's leadership as it advances its small molecule therapeutics for cancer and other diseases driven by deregulated transcription.
Kronos Bio's current pipeline includes two internally developed drug candidates, KB-0742 and KB-9558, targeting transcription factors in specific cancers.
Kronos Bio, Inc. (Nasdaq: KRON) reported strong financial results for the first quarter of 2024 with $152.0 million in cash, providing a cash runway into the second half of 2026. The company made progress on its clinical programs, with an update on KB-0742-1001 expected at ASCO. IND-enabling studies for KB-9558 are on track, with the first-in-human study set to begin in the first half of 2025. Kronos Bio also presented new data at the AACR Annual Meeting in April 2024, showcasing advancements in its p300 program and CDK9 inhibitor studies. Despite a net loss of $30.0 million for the quarter, the company remains focused on advancing its collaborations and internal discovery programs.
FAQ
What is the current stock price of Kronos Bio (KRON)?
What is the market cap of Kronos Bio (KRON)?
